Cleveland BioLabs (CBLI) Short Interest Ratio & Short Volume

Short interest is the volume of Cleveland BioLabs shares that have been sold short but have not yet been closed out or covered. As of August 13th, investors have sold 15,600 shares of CBLI short. 0.13% of Cleveland BioLabs' shares are currently sold short. Learn More on Cleveland BioLabs' current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.13% of Cleveland BioLabs' floating shares are currently sold short.

Cleveland BioLabs saw a decrease in short interest during the month of August. As of August 13th, there was short interest totaling 15,600 shares, a decrease of 76.1% from the previous total of 65,400 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Cleveland BioLabs currently has issued a total of 15,479,000 shares. Some of Cleveland BioLabs' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Cleveland BioLabs currently has a public float of 11,660,000 shares.

0.13% of Cleveland BioLabs' shares are currently sold short. Here is how the short interest of companies compare to Cleveland BioLabs: Bruush Oral Care Inc. (62.06%), Context Therapeutics Inc. (0.08%), Grifols, S.A. (2.32%), LAVA Therapeutics (1.50%), Mainz Biomed (2.34%), NLS Pharmaceutics Ltd. (1.54%), Pharvaris (0.10%), Aptevo Therapeutics Inc. (5.13%), Allarity Therapeutics, Inc. (9.18%), China SXT Pharmaceuticals, Inc. (4.78%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Block, Inc. ($9.67 billion), S&P Global Inc. ($7.87 billion), Advanced Micro Devices, Inc. ($7.80 billion), Analog Devices, Inc. ($7.03 billion), Sea Limited ($6.40 billion), Charter Communications, Inc. ($5.60 billion), Wayfair Inc. ($5.18 billion), Aon plc ($3.93 billion), CrowdStrike Holdings, Inc. ($2.52 billion), and Teladoc Health, Inc. ($2.49 billion). View all of the most shorted stocks.

Short selling CBLI is an investing strategy that aims to generate trading profit from Cleveland BioLabs as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Cleveland BioLabs occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of CBLI, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including CBLI, twice per month. The most recent reporting period available is August, 13 2021.